{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:17:06Z","timestamp":1778663826364,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Deutsche Derma Gesell"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30\u2010positive cutaneous T\u2010cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30\u2010positive CTCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We included 14 CD30\u2010positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3\u00a0months prior\/after BV treatment. RTx was mainly applied as a low\u2010dose scheme.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow\u2010up of 14.4\u00a0months, median progression\u2010free survival was 12.0\u00a0months, with a 1\u2010year rate of 34.0%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ddg.15897","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:50:01Z","timestamp":1759236601000},"page":"495-502","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Brentuximab vedotin and radiotherapy for CD30\u2010positive cutaneous T\u2010cell lymphoma \u2013 a retrospective multicenter analysis"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9836-0933","authenticated-orcid":false,"given":"Patrick","family":"Schummer","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Glatzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Schr\u00fcfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"},{"name":"Skinmed AG  Lenzburg Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingulf","family":"Lawrenz","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiooncology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2544-7197","authenticated-orcid":false,"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin  Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig\u2010Holstein  Kiel Germany"},{"name":"Medical School Hamburg  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svea","family":"H\u00fcning","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital of Dortmund  Dortmund Germany"},{"name":"Hautarztpraxis Schwelm  Schwelm Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"Stranzenbach","sequence":"additional","affiliation":[{"name":"Dermatologie\u2010Gevelsberg  Gevelsberg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Mannheim  Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-9848","authenticated-orcid":false,"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6293-2554","authenticated-orcid":false,"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital W\u00fcrzburg  W\u00fcrzburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2850"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy133"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31266-7"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004710"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2015.01.008"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2015.05.006"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26299"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115064"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13478"},{"issue":"15","key":"e_1_2_8_11_1","article-title":"Phase Ib study of brentuximab vedotin (BV) with low\u2010dose total skin electron beam (LD\u2010TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)","volume":"38","author":"Song S","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23925"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703470"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000479224"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.14740\/jh534"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac012"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-1931"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101279"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18563"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14342"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2024.11.011"}],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15897","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ddg.15897","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ddg.15897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T08:46:58Z","timestamp":1778662018000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ddg.15897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/ddg.15897"],"URL":"https:\/\/doi.org\/10.1111\/ddg.15897","archive":["Portico"],"relation":{},"ISSN":["1610-0379","1610-0387"],"issn-type":[{"value":"1610-0379","type":"print"},{"value":"1610-0387","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2025-02-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}